编辑文章 - 后台系统

编辑文章

编辑文章

文章标题：

关键字：

所属疾病：

所属类别：

标　　签：

文章主图*

点击“Select image”更换图片

Select image Change Remove

注意! 最佳图片尺寸800*800

内容详情：

<p style="margin:0cm 0cm 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="background:#fdfdfe"><span style="font-family:"微软雅黑","sans-serif""><a href="http://www.india-drugstore.com/p/wenda_detail.php?id=2015&art_cate_value=0&art_navid_value=2"><span style="color:#3498db;"><strong><span style="background-color:#f1c40f;">赛普替尼（Selpercatinib）（塞尔帕替尼292）</span></strong></span></a><span style="color:#05073b">和普拉替尼（Pralsetinib）是两种用于治疗RET突变阳性的晚期或转移性甲状腺癌的药物.</span></span></span></span></span></span></p>

<p style="margin:0cm 0cm 0.0001pt; text-align:justify"> </p>

<p align="left" style="text-align:left; margin:0cm 0cm 0.0001pt"><span style="font-size:10.5pt"><span style="font-family:Calibri,"sans-serif""><b><span style="font-size:12.0pt"><span style="background:#fdfdfe"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">靶点选择性</span></span></span></span></b><span style="font-size:12.0pt"><span style="background:#fdfdfe"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">：</span></span></span></span></span></span></p>

<ul>
	<li align="left" style="text-align:left; margin:0cm 0cm 0.0001pt"><span style="font-size:10.5pt"><span style="background:#fdfdfe"><span style="tab-stops:list 36.0pt"><span style="font-family:Calibri,"sans-serif""><b><span style="font-size:12.0pt"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">普拉替尼</span></span></span></b></span></span></span><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="background:#fdfdfe"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">（塞尔帕替尼292）</span></span></span></span></span><span style="background:#fdfdfe"><span style="tab-stops:list 36.0pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">：是一种高度选择性的RET激酶抑制剂，它通过抑制RET基因的突变点，阻断了该信号通路的异常激活。这种突变常见于甲状腺癌等恶性肿瘤中，普拉替尼针对这一突变点的选择性使其能够有效地抑制癌细胞的生长和扩散。</span></span></span></span></span></span></span></li>
</ul>

<p style="text-align:left; margin:0cm 0cm 0.0001pt"> </p>

<ul>
	<li align="left" style="text-align:left; margin:0cm 0cm 0.0001pt"><span style="font-size:10.5pt"><span style="background:#fdfdfe"><span style="tab-stops:list 36.0pt"><span style="font-family:Calibri,"sans-serif""><b><span style="font-size:12.0pt"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">赛普替尼</span></span></span></b><span style="font-size:12.0pt"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">：同样是一种RET激酶抑制剂，但它对RET突变的选择性略低于普拉替尼。此外，赛普替尼还具有对其他激酶如ROS1和ALK的抑制作用，因此其治疗范围更广</span></span></span></span></span></span></span></li>
</ul>

<p style="margin:0cm 0cm 0.0001pt; text-align:justify"> </p>

<p style="margin:0cm 0cm 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="background:#fdfdfe"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b">综上所述，赛普替尼在疗效、安全性和耐药性方面可能略优于普拉替尼，尤其是在治疗脑转移方面表现出显著优势。然而，具体选择哪种药物还需根据患者的具体情况和医生的建议来决定。</span></span></span></span></span></span></p>

<p style="margin:0cm 0cm 0.0001pt; text-align:justify"> </p>

<p style="margin:0cm 0cm 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri,"sans-serif""><span style="font-size:12.0pt"><span style="background:#fdfdfe"><span style="font-family:"微软雅黑","sans-serif""><span style="color:#05073b"><img alt="" src="../upload/66d57f566aa3a191168819.jpg" style="width: 270px; height: 400px;" /></span></span></span></span></span></span></p>

首页显示：

显示不显示

热门文章：

是否

阅读：